Patent 7645778 was granted and assigned to Bristol-Myers Squibb on January, 2010 by the United States Patent and Trademark Office.
The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.